Anteris Technologies (AVR) Share Scheme Meeting summary
Event summary combining transcript, slides, and related documents.
Share Scheme Meeting summary
12 Jan, 2026Opening remarks and agenda
Meeting convened to consider a scheme of arrangement for redomiciling to the US via acquisition by ATGC.
The meeting was held both in-person in Brisbane and virtually, with a quorum confirmed.
Only shareholders, proxies, corporate representatives, and attorneys could speak; visitors were welcomed.
Board and executive committee updates
Board members and key executives, including the CEO and company secretary, were introduced.
Legal advisors and share registry representatives were present to assist with meeting procedures.
Shareholder proposals
The sole item of business was the Share Scheme resolution to approve the scheme of arrangement.
The scheme involves ATGC acquiring all issued shares, making Anteris a wholly owned subsidiary and redomiciling to the US.
Latest events from Anteris Technologies
- A novel TAVR valve with proven durability and clinical benefits targets major market expansion.AVR
Barclays 28th Annual Global Healthcare Conference10 Mar 2026 - 2025 net loss widened to $94.2M on higher R&D, but liquidity strengthened by $320M in new equity.AVR
H2 20258 Mar 2026 - DurAVR demonstrates clinical superiority and rapid trial momentum, reshaping the TAVR landscape.AVR
TD Cowen 46th Annual Health Care Conference2 Mar 2026 - Two share issue ratifications were voted on with no shareholder questions; results to be released.AVR
EGM 202412 Jan 2026 - Option holders voted on exchanging Anteris options for ATGC options; results pending ASX release.AVR
Option Scheme Meeting12 Jan 2026 - Biomimetic TAVR valve targets $10B market with superior hemodynamics and pivotal study launch.AVR
Barclays 27th Annual Global Healthcare Conference26 Dec 2025 - OJEMDA's rapid adoption and robust pipeline drive steady growth and future market potential.AVR
TD Cowen 45th Annual Healthcare Conference26 Dec 2025 - US IPO, expanded R&D, and board expertise marked a pivotal year; all proposals recommended.AVR
AGM 202513 Dec 2025 - Regulatory approvals advanced the PARADIGM Trial, driving higher R&D spend and cash outflows.AVR
Q3 2025 TU23 Nov 2025